The global lymphoma treatment market size is expected to reach USD 26.4 billion by 2026, exhibiting a CAGR of 9.5%. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.
Access Sample Report of this report @ https://www.radiantinsights.com/research/lymphoma-market/request-sample
Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.
Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.
Further key findings from the report suggest:
- Non-Hodgkin lymphoma held the largest share in 2018 owing to prevalence of non-Hodgkin lymphoma and presence of blockbuster drugs.
- Hodgkin lymphoma is expected to be the fastest growing segment due to presence of strong product pipeline and increase in the number of label extension for existing drugs.
- Based on drug, Revlimid held the highest share in 2018 and is expected to grow at a significant rate during the forecast period. This can be attributed to growing use of this product in cancer treatment regimens.
- Rituxan/MabThera held the second largest share in 2018 owing to increasing use of this product in multiple indications and high prescription rate in major markets such as the U.S., Europe, and Japan.
- North America dominated in 2018, followed by Europe. This can be attributed to well-established healthcare infrastructure, high R&D expenditure, availability of novel drugs, and presence of key players.
- Asia Pacific is expected to be the fastest growing over the forecast period owing to increase in commercialization of products, rise in awareness about diseases and high unmet clinical needs.
- Some of the major players are Celgene Corporation; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Seattle Genetics, Inc.; Merck & Co., Inc.; Johnson & Johnson; Takeda Pharmaceutical Company Ltd.; Abbott Laboratories; and Eli Lilly and Company.
- Key players for lymphoma treatment market are adopting strategies such as collaborations, mergers & acquisitions, product development, product line extension, and regional expansion to increase their share. For instance, Seattle Genetics collaborated with Takeda Pharmaceuticals for commercialization of Adcetris in different regions other than North America.
Read Complete Report with TOC @ https://www.radiantinsights.com/research/lymphoma-market
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: [email protected]
